ImmunityBio
IBRX
126 hedge funds and large institutions have $311M invested in ImmunityBio in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 51 increasing their positions, 26 reducing their positions, and 16 closing their positions.
96% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 26
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
0.93% more ownership
Funds ownership: 7.23% → 8.16% (+0.93%)
1% more funds holding
Funds holding: 125 → 126 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less capital invested
Capital invested by funds: $390M → $311M (-$78.7M)
61% less call options, than puts
Call options by funds: $5.03M | Put options by funds: $13M
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$12.4M |
| 3 |
JP Morgan Chase
New York
|
+$6.3M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.23M |
| 5 |
BlackRock
New York
|
+$3.06M |
Top Sellers
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$3.57M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.43M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.43M |
| 4 |
Citigroup
New York
|
-$1.27M |
| 5 |
EGM
Engineers Gate Manager
New York
|
-$1.25M |
IBRX Hedge Fund Activity: Q3 2021 in Review
126 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2021, worth a combined $311M — down 20% from $390M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new IBRX positions and 16 closed out — a net gain of 4 holders — while 51 added to existing stakes and 26 trimmed.
The largest buyer was Vanguard Group, adding an estimated $16.2M. The largest seller was First Trust Advisors, exiting entirely with an estimated $3.57M sold.
- 126 institutional investors held ImmunityBio (IBRX) as of Q3 2021, up from 125 in Q2 2021.
- Funds reported $311M of ImmunityBio stock for Q3 2021, down 20% quarter-over-quarter.
- 20 funds opened new ImmunityBio positions in Q3 2021 and 16 closed out, a net change of +4 holders.
- The largest ImmunityBio buyer in Q3 2021 was Vanguard Group, an estimated $16.2M added.
- The largest ImmunityBio seller in Q3 2021 was First Trust Advisors, an estimated $3.57M sold.
Based on aggregated 13F filings for Q3 2021.